Ø Academia-Industry Partnership to Promote
Indigenous Technology Commercialization in Biotechnology Sector
·
National
Institute of Pharmaceutical Education and Research Raebareli signed a:
o Memorandum of Understanding (MoU),
o Confidential Disclosure Agreement (CDA),
and
o Technology Transfer Agreement
with
Lofty Laboratories.
·
The
collaboration aims to strengthen academia-industry partnerships in
pharmaceutical and biotechnology research, innovation and technology
commercialization.
·
Both
organisations agreed to commercialize an industry-ready technology developed at
NIPER-Raebareli.
·
The
partnership will also support joint research and development activities in
areas of mutual interest.
·
The
agreement includes collaborative participation in activities under the
Institute’s:
o Center of Excellence on Novel Drug Delivery
Systems (CoE-NDDS).
·
Shubhini A. Saraf stated that the collaboration
would help both institutions complement each other’s research programmes.
·
Prof.
Saraf also indicated that several additional technologies developed at the
Centre of Excellence may become ready for technology transfer by the end of the
year.
·
Nihar
Ranjan highlighted that commercialization of the technology would significantly
reduce the cost of gel-staining agents.
·
These
agents are widely used globally in:
o Gene studies,
o Cancer research,
o Nucleic acid-related disease research.
·
Indigenous
production of such gel-staining agents is expected to strengthen India’s
pharmaceutical and biotechnology sectors through reduced import dependence and
enhanced domestic innovation capabilities.
National Institute of Pharmaceutical
Education and Research (NIPER), Raebareli has signed a Memorandum of Understanding (MoU),
Confidential Disclosure Agreement
(CDA), and Technology
Transfer Agreement with Lofty
Laboratories, Hyderabad to foster multidirectional collaboration
in research, innovation, and technology commercialization.
This MoU marks a significant
step towards strengthening
academia-industry partnerships aimed at advancing pharmaceutical and biotechnology
research. During the signing ceremony, both the organizations agreed
to adopt an industry-ready technology developed at NIPER-Raebareli for further commercialization
and development. The collaboration will also include joint participation in research
and development activities in areas of mutual interest.
Speaking during the occasion,
the Director of NIPER-Raebareli, Prof. Shubhini A. Saraf,
stated that the MoU and technology transfer agreement would enable both institutions
to complement each other’s research programs in multiple ways, including collaborative
participation in the activities of the Institute’s
Center of Excellence on Novel Drug Delivery Systems
(CoE-NDDS).
Prof. Saraf also highlighted
the importance of the technology developed in CoE and
expressed hope that several more technologies from the Institute would be ready
for transfer by the end of the year.
Addressing the gathering, Prof.
Nihar Ranjan, Head, CoE-NDDS explained that commercialization
of the present technology would significantly reduce the cost of gel-staining agents,
which are extensively used worldwide in biology-related research, particularly in
studies involving genes, cancer, and other nucleic acid-related diseases. He added
that indigenous production of such novel gel-staining agents would contribute substantially
towards strengthening India’s pharmaceutical and biotechnology sectors.